Brokers Set Expectations for Aquinox Pharmaceuticals, Inc.’s FY2017 Earnings (AQXP)
Aquinox Pharmaceuticals, Inc. (NASDAQ:AQXP) – Stock analysts at Leerink Swann upped their FY2017 earnings per share (EPS) estimates for Aquinox Pharmaceuticals in a research report issued on Tuesday. Leerink Swann analyst P. Matteis now forecasts that the company will earn ($2.21) per share for the year, up from their previous forecast of ($2.22).
Other equities analysts have also recently issued reports about the stock. BidaskClub cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, July 28th. Zacks Investment Research lowered shares of Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, May 9th. Canaccord Genuity set a $22.00 price objective on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday. ValuEngine upgraded shares of Aquinox Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Finally, Cantor Fitzgerald set a $28.00 price objective on shares of Aquinox Pharmaceuticals and gave the company a “buy” rating in a research report on Tuesday, May 9th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Aquinox Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $22.50.
COPYRIGHT VIOLATION NOTICE: “Brokers Set Expectations for Aquinox Pharmaceuticals, Inc.’s FY2017 Earnings (AQXP)” was originally posted by Daily Political and is the property of of Daily Political. If you are reading this report on another domain, it was copied illegally and republished in violation of US and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/brokers-set-expectations-for-aquinox-pharmaceuticals-inc-s-fy2017-earnings-aqxp.html.
Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) opened at 13.55 on Thursday. Aquinox Pharmaceuticals has a 12-month low of $8.76 and a 12-month high of $19.97. The company’s market capitalization is $317.67 million. The stock’s 50 day moving average is $14.58 and its 200-day moving average is $15.51.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings data on Tuesday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.59).
Several large investors have recently added to or reduced their stakes in the company. Sphera Funds Management LTD. purchased a new stake in Aquinox Pharmaceuticals during the second quarter valued at about $874,000. Archon Partners LLC raised its stake in Aquinox Pharmaceuticals by 44.0% in the second quarter. Archon Partners LLC now owns 18,000 shares of the company’s stock valued at $253,000 after buying an additional 5,500 shares during the period. Bank of New York Mellon Corp raised its stake in Aquinox Pharmaceuticals by 16.5% in the second quarter. Bank of New York Mellon Corp now owns 23,260 shares of the company’s stock valued at $327,000 after buying an additional 3,299 shares during the period. Alps Advisors Inc. raised its stake in Aquinox Pharmaceuticals by 4.7% in the second quarter. Alps Advisors Inc. now owns 21,090 shares of the company’s stock valued at $297,000 after buying an additional 939 shares during the period. Finally, Investment Centers of America Inc. purchased a new stake in Aquinox Pharmaceuticals during the first quarter valued at about $172,000. Hedge funds and other institutional investors own 98.32% of the company’s stock.
In other news, insider David Main sold 15,625 shares of the firm’s stock in a transaction dated Monday, June 5th. The shares were sold at an average price of $13.26, for a total value of $207,187.50. Following the completion of the sale, the insider now owns 77,530 shares in the company, valued at approximately $1,028,047.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 2.70% of the stock is owned by company insiders.
Aquinox Pharmaceuticals Company Profile
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.